Posts Strong Q4 & FY26 Results, Recommends Dividend
Marksans Pharma Limited · MARKSANS · NSE ·
• <b>FY26 Performance (YoY):</b> Revenue grew 12.5% to ₹29,509 million. Profit After Tax (PAT) increased by 9.8% to ₹4,200 million. Basic EPS stood at ₹9.22. • <b>Q4 FY26 Performance (YoY):</b> Revenue surged 20.8% to ₹8,561 million. PAT jumped 64.3% to ₹1,490 million. Basic EPS…